Increased composite outcomes of reduction in pain together with improvement in function in those with CLBP of shorter duration than 68 months, the median for the study; however, the composite outcomes of pain and function did not reach statistical significance across the entire study
can somebody explain what the above means?
do they achieve meaningful pain reduction or they don’t???
- Forums
- ASX - By Stock
- MSB
- Ann: Mesoblast Phase 3 Chronic Low Back Pain Results
Ann: Mesoblast Phase 3 Chronic Low Back Pain Results, page-122
Featured News
Add MSB (ASX) to my watchlist
(20min delay)
|
|||||
Last
$1.57 |
Change
-0.210(11.8%) |
Mkt cap ! $1.792B |
Open | High | Low | Value | Volume |
$1.72 | $1.74 | $1.52 | $15.63M | 9.716M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 5127 | $1.57 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.57 | 39613 | 3 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 5127 | 1.565 |
3 | 15000 | 1.560 |
2 | 8950 | 1.545 |
3 | 52000 | 1.540 |
1 | 100000 | 1.525 |
Price($) | Vol. | No. |
---|---|---|
1.570 | 14365 | 2 |
1.580 | 57756 | 6 |
1.585 | 5500 | 1 |
1.590 | 3123 | 1 |
1.600 | 5000 | 1 |
Last trade - 16.10pm 15/11/2024 (20 minute delay) ? |
Featured News
MSB (ASX) Chart |
The Watchlist
ACW
ACTINOGEN MEDICAL LIMITED
Will Souter, CFO
Will Souter
CFO
Previous Video
Next Video
SPONSORED BY The Market Online